GlassScriptPhysician profile
Jonathan M Carp
NPI 1922156843
$616.03
in general payments reported to CMS, 2019-2025
12 companies · $285 in 2025
The $285 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.30 · 2020: $20.63 · 2023: $72.62 · 2024: $224 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $581.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $296.91 | 2020-2025 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $70.11 | 2019-2025 | Blu-U, Odomzo |
| Ucb, INC. | $42.20 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $32.21 | 2024 | Dupixent |
| Incyte Corporation | $27.80 | 2025 | Opzelura |
| Almirall LLC | $27.57 | 2025 | Seysara |
| Organogenesis INC. | $27.18 | 2025 | Puraply Wound Matrix |
| Janssen Biotech, INC. | $24.91 | 2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $18.72 | 2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.07 | 2025 | Siliq, Jublia, Cabtreo |
| Paratek Pharmaceuticals, INC. | $16.27 | 2024 | Nuzyra |
| Cipher Pharmaceuticals US LLC | $15.08 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Carp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.